Study of Tumor Tissue Samples From Patients Who Have Undergone Surgery for Advanced Stage III or Stage IV Ovarian Epithelial Cancer
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Stage IIIA Ovarian Cancer
- Stage IIIB Ovarian Cancer
- Stage IIIC Ovarian Cancer
- Stage IV Ovarian Cancer
- Type
- Observational
- Design
- Not Provided
Participation Requirements
- Age
- Younger than 125 years
- Gender
- Only males
Description
PRIMARY OBJECTIVES: I. To validate the ability of intratumoral tumor-infiltrating T lymphocytes (TILs) to predict progression-free survival (PFS) in patients with suboptimally debulked advanced stage III or IV ovarian epithelial cancer. II. To validate the ability of intratumoral TILs to predict PFS...
PRIMARY OBJECTIVES: I. To validate the ability of intratumoral tumor-infiltrating T lymphocytes (TILs) to predict progression-free survival (PFS) in patients with suboptimally debulked advanced stage III or IV ovarian epithelial cancer. II. To validate the ability of intratumoral TILs to predict PFS in patients with optimally debulked disease. SECONDARY OBJECTIVES: I. To validate the ability of intratumoral TILs to predict overall survival of patients with suboptimally debulked disease. II. To validate the ability of intratumoral TILs to predict overall survival of patients with optimally debulked disease. OUTLINE: Patients are stratified according to status of debulked disease (suboptimal vs optimal). Previously collected tumor tissue samples are analyzed for tumor-infiltrating lymphocytes (TIL) via immunohistochemistry and double immunofluorescence assays using standard immunostaining.
Tracking Information
- NCT #
- NCT01000259
- Collaborators
- National Cancer Institute (NCI)
- Investigators
- Principal Investigator: George Coukos Gynecologic Oncology Group